| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8753665 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8846072 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8153149 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8153661 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
| US11771624 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
Posimir is owned by Innocoll.
Posimir contains Bupivacaine.
Posimir has a total of 6 drug patents out of which 0 drug patents have expired.
Posimir was authorised for market use on 01 February, 2021.
Posimir is available in solution, extended release;infiltration dosage forms.
Posimir can be used as method for providing sustained local anesthesia for at least 24 hours, to produce post-surgical analgesia.
The generics of Posimir are possible to be released after 12 January, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 01, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours; To produce post-surgical analgesia
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
